Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of leontopodium leontopodioides to preparation of medicine for treating pulmonary fibrosis

A technology of pulmonary fibrosis and edelweiss, which is applied in the field of edelweiss for the preparation of medicines for treating pulmonary fibrosis, and can solve problems such as no edelweiss

Active Publication Date: 2021-10-29
INNER MONGOLIA UNIV FOR THE NATITIES
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In summary, there is no relevant report that edelweiss is used for the preparation of medicines for the treatment of pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of leontopodium leontopodioides to preparation of medicine for treating pulmonary fibrosis
  • Application of leontopodium leontopodioides to preparation of medicine for treating pulmonary fibrosis
  • Application of leontopodium leontopodioides to preparation of medicine for treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0043] Crush the edelweiss medicinal material and pass through No. 2 sieve, soak 100g of the sieved edelweiss medicinal material powder in water, heat and reflux for extraction 3 times; each time the amount of water is 1000mL, soak for 5h each time, and extract for 4h by heating and reflux each time ; The combined extracts were filtered and concentrated under reduced pressure to obtain 19.8g edelweiss extract. Put it in a 4°C refrigerator and refrigerate it. It can be diluted and dissolved with water when used.

experiment example 1

[0045] 1. Animal modeling and experimental methods

[0046] Healthy SD rats, weighing 300-350 g, were used as animals, purchased from Changchun Yisi Experimental Animal Technology Co., Ltd.

[0047] Rats were randomly divided into normal control group, bleomycin model control group (model control group), edelweiss administration group (edelweiss low-dose group, edelweiss middle-dose group, edelweiss high-dose group, edelweiss given The edelweiss extract used in the medicine group is the edelweiss extract prepared in Preparation Example 1) and the prednisone hydrochloride positive drug group (5mg / kg), a total of 6 groups, 10 in each group. Each group was intragastrically administered the corresponding test drug, once a day, until sacrificed, and the model control group and normal control group were intragastrically administered distilled water. Except for the blank group, the other groups established rat pulmonary fibrosis models by injecting bleomycin 5 mg / kg into the trachea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of leontopodium leontopodioides to preparation of a medicine for treating pulmonary fibrosis.

Description

technical field [0001] The invention relates to the use of edelweiss for preparing medicine for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is a chronic inflammatory interstitial lung disease of unknown cause, such as interstitial pneumonia and lung diseases caused by connective tissue can lead to pulmonary fibrosis. In recent years, the incidence of pulmonary fibrosis has been gradually increasing, with a high mortality rate and serious harm to human health, which is attracting widespread attention all over the world. The main clinical manifestations of pulmonary fibrosis patients are progressive dyspnea, and eventually develop hypoxemia and respiratory failure and die. The average survival time after diagnosis is 3 years. The etiology of pulmonary fibrosis is complex, the mechanism is unknown, and there is still a lack of effective therapeutic drugs. Currently, immunosuppressive and glucocorticoid drugs are mainly used in the clinical tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/28A61P11/00
CPCA61K36/28A61P11/00A61K2236/331A61K2236/39A61K2236/51
Inventor 马茜茜
Owner INNER MONGOLIA UNIV FOR THE NATITIES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com